Key result
Accumulating patient cardiovascular co-morbidities strongly inversely correlated with the regenerative capacity of their cardiac explant-derived cells, including reduced improvements in left ventricular ejection fraction in a mouse model.
Why the study?
Does the burden of cardiovascular risk factors reduce the regenerative capacity of human cardiac explant-derived cells in a mouse model of myocardial infarction?
Observational (n=32)
Blinded to patient comorbidities and treatment allocation
No
Does the burden of cardiovascular risk factors reduce the regenerative capacity of human cardiac explant-derived cells in a mouse model of myocardial infarction?
Accumulating medical co-morbidities in patients reduce the regenerative capacity and pro-cardiogenic cytokine production of their cardiac explant-derived stem cells.
Answers are grounded in this paper and cite their sources.
Comorbidities may impair cardiac explant-derived cell function; hypothesis-generating for autologous cell therapy efficacy in high-risk patients.
BACKGROUND: Although patient-sourced cardiac stem cells repair damaged myocardium, the extent to which medical co-morbidities influence cardiac-derived cell products is uncertain. Therefore, we investigated the influence of atherosclerotic risk factors on the regenerative performance of human cardiac explant-derived cells (EDCs). METHODS: In this study, the Long Term Stratification for survivors of acute coronary syndromes model was used to quantify the burden of cardiovascular risk factors within a group of patients with established atherosclerosis. EDCs were cultured from human atrial appendages and injected into immunodeficient mice 7 days post-left coronary ligation. Cytokine arrays and enzyme linked immunoassays were used to determine the release of cytokines by EDCs in vitro, and echocardiography was used to determine regenerative capabilities in vivo. RESULTS: EDCs sourced from patients with more cardiovascular risk factors demonstrated a negative correlation with production of pro-healing cytokines (such as stromal cell derived factor 1α) and exosomes which had negative effects on the promotion of angiogenesis and chemotaxis. Reductions in exosomes and pro-healing cytokines with accumulating medical co-morbidities were associated with increases in production of the pro-inflammatory cytokine interleukin-6 (IL-6) by EDCs. Increased patient co-morbidities were also correlated with significant attenuation in improvements of left ventricular ejection fraction. CONCLUSIONS: The regenerative performance of the earliest precursor cell population cultured from human explant tissue declines with accumulating medical co-morbidities. This effect is associated with diminished production of pro-cardiogenic cytokines and exosomes while IL-6 is markedly increased. Predictors of cardiac events demonstrated a lower capacity to support angiogenesis and repair injured myocardium in a mouse model of myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Mayfield et al. (2016) conducted an observational in Established atherosclerosis requiring cardiac surgery (n=32). Accumulating medical co-morbidities (LTS score) vs. Fewer medical co-morbidities (lower LTS score) was evaluated on Improvement in left ventricular ejection fraction (LVEF) at 3 weeks in a mouse model (r = -0.7, p=0.003). Accumulating patient cardiovascular co-morbidities strongly inversely correlated with the regenerative capacity of their cardiac explant-derived cells, including reduced improvements in left ventricular ejection fraction in a mouse model.
Synapse has enriched 10 related papers. Consider them for comparative context: